MARKET

PEPG

PEPG

PepGen Inc
NASDAQ
5.20
-0.07
-1.33%
Pre Market: 5.20 0 0.00% 08:00 12/19 EST
OPEN
5.25
PREV CLOSE
5.27
HIGH
5.61
LOW
5.08
VOLUME
100
TURNOVER
0
52 WEEK HIGH
6.72
52 WEEK LOW
0.8801
MARKET CAP
357.49M
P/E (TTM)
-1.8336
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PEPG last week (1208-1212)?
Weekly Report · 4d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 12/11 21:05
PepGen Inc. Files Initial Statement of Beneficial Ownership for Chief Business & Legal Officer Joseph Vittiglio
Reuters · 12/10 22:05
How Much Upside is Left in PepGen (PEPG)? Wall Street Analysts Think 75.44%
NASDAQ · 12/10 14:55
PepGen Grants Stock Options to New Chief Business and Legal Officer
Reuters · 12/09 12:00
PEPGEN REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4) TO NEWLY APPOINTED CHIEF BUSINESS AND LEGAL OFFICER
Reuters · 12/09 12:00
Meihua International Medical Technologies, Fly-E Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga · 12/08 13:03
PepGen Inc. Appoints New Chief Business Officer
TipRanks · 12/08 12:32
More
About PEPG
PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.

Webull offers PepGen Inc stock information, including NASDAQ: PEPG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PEPG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PEPG stock methods without spending real money on the virtual paper trading platform.